Psoriasis Clinical Trial

Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

Summary

Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.

View Full Description

Full Description

Same as above.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Moderate to severe psoriasis involving 3-20% of the body surface area

Exclusion Criteria:

Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® Spray or more than 100 grams per week of Taclonex® Ointment
Subjects having psoriasis that involves the scalp, face, or groin

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

122

Study ID:

NCT00437255

Recruitment Status:

Completed

Sponsor:

Galderma R&D

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

Minnesota Clinical Study Center
Fridley Minnesota, 55432, United States
DermResearch, Inc.
Austin Texas, 78759, United States
J & S Studies, Inc.
Bryan Texas, 77802, United States
Baylor Research Institute
Dallas Texas, 75230, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

122

Study ID:

NCT00437255

Recruitment Status:

Completed

Sponsor:


Galderma R&D

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider